News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Case Study: Off-Target Assessment for Beta-Secretase 1 Inhibitors Optimization

Symmetry's Global Mechanism of Action (GMoA) model helps anticipate potential off-target safety liabilities of new structures early in drug discovery. This case study is performed with molecules reported in a recent paper describing the optimization of compounds for the potential treatment of Alzheimer ’s disease, minimizing cardiovascular liabilities (hERG channel blockade).

To receive your PDF copy of this Case Study, please contact